Cytoreductive surgery following neoadjuvant chemotherapy in patients with initial unresectable stage IV ovarian cancer

Patients with stage IV Epithelial Ovarian Cancer (EOC) are often poor candidates for primary cytoreductive surgery (PCS) due to disease location, volume of disease, and patients factors, hence are treated with neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS). In patients where ICS is unlikely to result in optimal cytoreduction, the benefit of ICS over systemic treatment alone remains unclear. We aimed to compare survival outcomes in stage IV patients treated with NACT+ICS versus chemotherapy alone and to compare clinical and radiological characteristics in these groups.